# How Universities are Supporting the Commercialisation Ecosystem


Dr Peter Gooden

Director of Research and Enterprise Services



### **Outline**

- Research and Enterprise @ UH
- Showcasing collaborative commercialisation within Healthtech
- A UH commercialisation case study



## Facts and figures







### Size and shape of the University



We have a turnover of circa £380 million



We have invested £41.5 million into our campuses over the past year



We have a total staff population of 3063 (UH only), 70% of whom are FT



Our total student population is nearly 35,000



Our 13,000-strong international student community come from more than 140 countries



We offer 550 undergraduate, postgraduate and research degrees across six schools of study

#### Research successes



We are <u>the</u> top-ranked post-92 university for research impact



90% of our research has been judged as "internationally excellent" or "world-leading" in the REF 2021



We're in the top 25% of all universities nationally for research impact



We have risen 21 places in the REF 2021 rankings from 83rd to 62nd



In the Postgraduate Research Experience Survey (PRES) 2023 our overall satisfaction score was 81%, putting us higher than all our benchmark comparators (Russell Group, Alliance, Post-92 & global). lop 25%

of all UK universities for research impact

number of businesses we supported (2019-22)

£30m

additional revenue those businesses generated from our support\*

full-time jobs those businesses created

**740** 

hours of business mentoring and consultancy we provided (2021-22)

£12.3m

value of research and consultancy services we provided (2020-21)

hours of business 3.596 advice we provided on innovation, research and development

hours of business advice we provided on skills and training

businesses that approached us first

amount our business **£40**m amount our business support is estimated to baye generated (2019-2 have generated (2019-22)



University of Hertfordshire Powering Impact report

### **Herts Open for Business**

Supporting businesses to grow through innovation

To maximise knowledge exchange income and drive impact by enabling R&D collaborations with industry and other key organisations.

#### **KEY MESSAGES TO OUR CLIENTS**

- We have expertise and facilities to enable your business to solve problems or access new opportunities
- We deliver impact for our clients
- Your future success is our motivation
- We want to build a long-term relationship and provide value at every stage of your innovation journey



#### Research and Insights through KE

- Research and Innovation collaborations with industry driving added value and impact
- Facilitating the development of applications through bid writing, coordination and guidance on finance, legal and policies
- 2023/24: £14.2m research grant awards +
   £13.5m for new Biodetection Hub
- Currently, over 50 long term research collaborations are underway supported by KE funding (e.g. KTPs, KEEP+, ERDF)
- Achieved additional grant income of over £35M across capital, innovation and skills provision since 2020.
















# HTCC

Healthcare Technologies Capability Connector











#### **Healthcare Technologies Capability Connector**



The UK's Life Science sector is vibrant and of vital importance to the economy. However, a **key challenge as it looks to grow and remain competitive, is to create the conditions for innovations to scale at pace** by facilitating access to space, specialist labs, equipment, research and manufacturing expertise.

HTCC aims to respond to this challenge by linking -up London -based SMEs and innovators to ecosystems in the larger Hertfordshire and Bedfordshire regions which are ready to support innovation at scale. Equally, we are keen to link up investment networks in London, with SMEs innovating across the wider region.












#### The programme

- Academic research translation **Proof of Concept funding** and commercialisation support 01 provided by all partners to new academic innovations emerging from within the three partner institutions.
- **Accelerator programme** for UK SMEs, involving access to senior academic expertise, access to 02 specialist infrastructure and support across the partnership including incubator spaces and labs.
- MarketReady Academy training and development of commercialisation skills within research 03 cohorts as well as executive level mentoring for founders and entrepreneurs.









#### **PROOF OF CONCEPT**

£400k invested 8 projects

**Developing a R&D and commercialisation strategy** 



# PROOF OF CONCEPT FUNDING

PROJECT	DESCRIPTION
MICROBIA	Microbial based solution to defeat neurodegenerative disease.
EMBED	Accelerating bone healing with implantable electronics.
SIFTR	Targeting tumours with drugs designed in humans.
INFORMIX	Pharmaceutical microstructure measurement.
PULMONARY INFECTION	Real-time diagnosis of pulmonary infection for patients in intensive care.
VIBROSENSE	Device to improve sensitivity in stroke patients.
IMPERIAL DIAGNOSTICS	Early detection and monitoring of cancer.
SEPSIS	Detection of biomarkers for enhanced patient outcomes.

#### **PROOF OF CONCEPT**

£400k invested

8 projects

**Developing a R&D and commercialisation strategy** 



## PROOF OF CONCEPT FUNDING

КРІ	DESCRIPTION
4 POC projects advancing to TRL 6	<ul> <li>Embed Biotech (IMP)</li> <li>Pharmaceutical Microstructure (UH)</li> <li>Vibrosense (UH)</li> <li>Microbia (IMP)</li> </ul>
2 exploitation vehicles developed	<ul> <li>Embed Biotech (IMP)</li> <li>SIFTR (IMP)</li> <li>Informix Pharma (UH)</li> </ul>
3 new patents filed.	<ul> <li>Pulmonary Infection (CU)</li> <li>Pharmaceutical Microstructure (UH)</li> <li>Microbia (IMP)</li> </ul>

## ACCELERATION PROGRAMME

Over £500k invested in 15 SMEs

**R&D** and commercialisation support

**Academic expertise** 

1-2-1 mentoring



## O2 ACCELERATION


КРІ	DESCRIPTION
6 embedded researchers providing meaningful value for SME's	8 embedded researchers involved in 15/17 projects (2 from UH and 6 from CU).
1-2-1 mentoring delivered.	300 hrs 1-2-1 mentoring delivered.
5 new products/ services ready for market	<ul> <li>Reneural (UH)</li> <li>Briteyellow (UH)</li> <li>Aga Nanotech (UH)</li> <li>SurgeryAl (UH)</li> <li>Cambridge Surgical Models (CU)</li> <li>Neurobright (CU)</li> <li>GoAssistive (IC)</li> </ul>
3 supported companies receiving grant funding or investment	<ul> <li>Srotas Health (UH)</li> <li>Reneural (UH)</li> <li>GoAssistive (IMP)</li> <li>IngeniumAI (IMP)</li> <li>Aga Nanotech (UH)</li> <li>UpLyft (IMP)</li> </ul>
3 new research collaboration beyond accelerator projects.	<ul> <li>Aga Nanotech (UH)</li> <li>UpLyft (IC)</li> <li>GoAssistive (IC)</li> <li>Neurobright (CU)</li> </ul>





## 03

## MarketReady Academy



КРІ	DESCRIPTION
30 hrs of training delivered	38/30 hrs of training delivered.
40 researchers trained	49/40 researchers trained.
Up to 80 research staff attending training	185 research staff attending training.

## Case study: ImmuONE – a TT success story

#### 'A novel in-vitro model for predicting lung toxicity'

- 2018: UH PhD student Abigail Martin iCURe Accelerator submission based on LMS research – awarded £35k for market awareness
- 2019: iCURe program completed and ImmuONE registered
- 2019: ImmuONE awarded £300k funding from InnovateUK for product commercialisation
- 2019: ImmuONE begins lease agreement with UH for renting laboratory space in Science building
- 2020: ImmuONE joins UH Business Incubator
- 2021: ImmuONE awarded CRACK-IT grant (£600k) to improve in vitro assays to be free from animal-derived products
- 2022: Moves to 1800 sqft grow-on facilities in Stevenage
- 2023: Received £2m investment from Mercia Ventures and Pioneer Group
- 2025: ImmuONE currently employs ~15 staff with significant turnover



### Case study: ImmuONE – a TT success story

'A novel in-vitro model for predicting lung toxicity'



## Female-led ImmuONE bags £2M for 3D human lung model to test drugs





## Thank you

p.gooden@herts.ac.uk

be@herts.ac.uk



herts.ac.uk